Discovery and evaluation of inhibitors of human ceramidase

Molecular Cancer Therapeutics

Volumn 10, Issue 11, 2011, Pages 2052-2061

  Draper, Jeremiah M ^a   Xia, Zuping ^a   Smith, Ryan A ^b   Zhuang, Yan ^b   Wang, Wenxue ^a   Smith, Charles D ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b APOGEE BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDASE; CERANIB 1; CERANIB 2; PACLITAXEL; SPHINGOSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SIZE; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; DIAGNOSTIC TEST ACCURACY STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CERAMIDASES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; SMALL MOLECULE LIBRARIES;

EID: 81055124269     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0365     Document Type: Article

References (50)

1. Snider AJ, Alexa Orr Gandy K, Obeid LM. Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie 2010;92:707-15.
2. Leong WI, Saba JD. S1P metabolism in cancer and other pathological conditions. Biochimie 2010;92:716-23.
3. Nixon GF. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol 2009;158:982-93.
4. Maceyka M, Milstien S, Spiegel S. Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling. J Lipid Res 2009;50:S272-6.
5. Cowart LA. Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol Metab 2009;20:34-42.
6. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008;49:413-40.
7. Billich A, Baumruker T. Sphingolipid metabolizing enzymes as novel therapeutic targets. Subcell Biochem 2008;49:487-522.
8. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J 1998;335:465-80. (Pubitemid 28515396)
9. Perry DK, Hannun YA. The role of ceramide in cell signaling. Biochim Biophys Acta 1998;1436:233-43.
10. Perry DK, Kolesnick RN. Ceramide and sphingosine 1-phosphate in anti-cancer therapies. Cancer Treat Res 2003;115:345-54.
11. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003;22:5897-906. (Pubitemid 37176710)
12. Olivera A, Spiegel S. Sphingosine kinase: a mediator of vital cellular functions. Prostaglandins 2001;64:123-34. (Pubitemid 32452286)
13. Spiegel S, Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 2002;277:25851-4. (Pubitemid 34967061)
14. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9:139-50. (Pubitemid 351158911)
15. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4:604-16. (Pubitemid 39025055)
16. Bielawska A, Linardic CM, Hannun YA. Ceramide-mediated biology. Determination of structural and stereospecific requirements through the use of N-acyl-phenylaminoalcohol analogs. J Biol Chem 1992;267:18493-7.
17. Bielawska A, Greenberg MS, Perry D, Jayadev S, Shayman JA, McKay C, et al. (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem 1996;271:12646-54. (Pubitemid 26160940)
18. Raisova M, Goltz G, Bektas M, Bielawska A, Riebeling C, Hossini AM, et al. Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett 2002;516:47-52. (Pubitemid 34311931)
19. Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, et al. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 2004;58:382-93. (Pubitemid 38295032)
20. Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001;61:1233-40. (Pubitemid 32174448)
21. Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol 1999;15:541-6.
22. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 2009;8:809-20.
23. Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM, Gold DV. Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Cancer Res 2004;64:8405-10. (Pubitemid 39491780)
24. Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, et al. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther 2006;13:1045-51. (Pubitemid 44760102)
25. Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 2000;29:137-46.
26. Elojeimy S, Liu X, McKillop JC, El-Zawahry AM, Holman DH, Cheng JY, et al. Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther 2007;15:1259-63.
27. Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, et al. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 2009;13:1449-58.
28. Musumarra G, Barresi V, Condorelli DF, Scire S. A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol Chem 2003;384:321-7. (Pubitemid 36348334)
29. Strelow A, Bernardo K, Adam-Klages S, Linke T, Sandhoff K, Kronke M, et al. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med 2000;192:601-12.
30. Zhu Q, Jin JF, Shan XH, Liu CP, Mao XD, Xu KF, et al. Chronic activation of neutral ceramidase protects beta-cells against cytokineinduced apoptosis. Acta Pharmacol Sin 2008;29:593-9. (Pubitemid 351601443)
31. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, et al. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther 2009;17:430-8.
32. Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, et al. Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. Oncol Rep 2006;16:907-13.
33. Modrak DE, Leon E, Goldenberg DM, Gold DV. Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol Cancer Res 2009;7:890-6.
34. Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, et al. Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci 2008;13:2293-8. (Pubitemid 351589254)
35. Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, et al. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2008;61:231-42. (Pubitemid 350160321)
36. Grijalvo S, Bedia C, Triola G, Casas J, Llebaria A, Teixido J, et al. Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues. Chem Phys Lipids 2006;144:69-84. (Pubitemid 44537272)
37. Bedia C, Canals D, Matabosch X, Harrak Y, Casas J, Llebaria A, et al. Cytotoxicity and acid ceramidase inhibitory activity of 2-substituted aminoethanol amides. Chem Phys Lipids 2008;156:33-40.
38. Bedia C, Casas J, Garcia V, Levade T, Fabrias G. Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases. Chembiochem 2007;8:642-8. (Pubitemid 47194856)
39. Xia Z, Draper JM, Smith CD. Improved synthesis of a fluorogenic ceramidase substrate. Bioorg Med Chem 2010;18:1003-9.
40. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12. (Pubitemid 20213250)
41. Bu S, Yamanaka M, Pei H, Bielawska A, Bielawski J, Hannun YA, et al. Dihydrosphingosine 1-phosphate stimulates MMP1 gene expression via activation of ERK1/2-Ets1 pathway in human fibroblasts. Faseb J 2006;20:184-6. (Pubitemid 43100508)
42. Stiban J, Fistere D, Colombini M. Dihydroceramide hinders ceramide channel formation: implications on apoptosis. Apoptosis 2006;11:773-80. (Pubitemid 43876846)
43. Bernardo K, Hurwitz R, Zenk T, Desnick RJ, Ferlinz K, Schuchman EH, et al. Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem 1995;270:11098-102.
44. Tani M, Okino N, Mitsutake S, Tanigawa T, Izu H, Ito M. Purification and characterization of a neutral ceramidase from mouse liver. A single protein catalyzes the reversible reaction in which ceramide is both hydrolyzed and synthesized. J Biol Chem 2000;275:3462-8. (Pubitemid 30083054)
45. Hu W, Xu R, Sun W, Szulc ZM, Bielawski J, Obeid LM, et al. Alkaline ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides, and its down-regulation inhibits both cell proliferation and apoptosis. J Biol Chem 2010;285:7964-76.
46. Mao Z, Sun W, Xu R, Novgorodov S, Szulc ZM, Bielawski J, et al. Alkaline ceramidase 2 (ACER2) and its product dihydrosphingosine mediate the cytotoxicity of N-(4-hydroxyphenyl)retinamide in tumor cells. J Biol Chem 2010;285:29078-90.
47. Sun W, Jin J, Xu R, Hu W, Szulc ZM, Bielawski J, et al. Substrate specificity, membrane topology, and activity regulation of human alkaline ceramidase 2 (ACER2). J Biol Chem 2010;285:8995-9007.
48. Sietsma H, Veldman RJ, Kok JW. The involvement of sphingolipids in multidrug resistance. J Membr Biol 2001;181:153-62. (Pubitemid 32548063)
49. Hendrich AB, Michalak K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr Drug Targets 2003;4:23-30. (Pubitemid 36131638)
50. Claassen G, Brin E, Crogan-Grundy C, Vaillancourt MT, Zhang HZ, Cai SX, et al. Selective activation of apoptosis by a novel set of 4-aryl-3- (3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones through a Myc-dependent pathway. Cancer Lett 2009;285:243-9.